Stocklytics Platform
Asset logo for symbol BEAM
Beam Therapeutics
BEAM61
$23.44arrow_drop_up0.17%$0.04
Asset logo for symbol BEAM
BEAM61

$23.44

arrow_drop_up0.17%
Key Stats
Open$23.86
Prev. Close$23.40
EPS-1.58
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range23.23
24.45
52 Week Range16.95
49.50
Ratios
EPS-1.58
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.87%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

BEAM-
US Healthcare Sector-
US Market-
warning

BEAM / Market

BEAM lose to the US Market which returned 1.31% over the last twenty four hours.
warning

BEAM / Healthcare Sector

BEAM lose to the US Healthcare sector which returned 2.66% over the last twenty four hours.

Beam Therapeutics (BEAM) Statistics

Beam Therapeutics Inc (BEAM) is a leading biotechnology company that specializes in developing precision genetic medicines. The company is focused on utilizing base editing technology to create precise changes in the DNA of patients, aiming to treat a wide range of diseases. With its innovative platform, Beam Therapeutics has the potential to revolutionize the field of genetic medicine.
When it comes to the valuation metrics of Beam Therapeutics Inc, the company has shown promising results. The stock currently trades at a reasonable price-to-sales ratio, indicating that it is being valued fairly by the market. Additionally, Beam Therapeutics has a solid enterprise-to-EBITDA ratio, which suggests that the company is generating healthy profits relative to its overall enterprise value.
add Beam Therapeutics  to watchlist

Keep an eye on Beam Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Beam Therapeutics (BEAM) stock's performance compared to its sector and the market over the past year?

Over the past year, Beam Therapeutics (BEAM) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 27.09%, Beam Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 48.15%, it has fallen short of the market average. This comparison highlights Beam Therapeutics 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Beam Therapeutics (BEAM) stock?

The PE ratio for Beam Therapeutics (BEAM) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Beam Therapeutics (BEAM) stock?

The Earnings Per Share (EPS) for Beam Therapeutics (BEAM), calculated on a diluted basis, is -$1.58. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Beam Therapeutics (BEAM) stock?

The operating margin for Beam Therapeutics (BEAM) is -746.4%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Beam Therapeutics (BEAM) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Beam Therapeutics (BEAM) is -$160.83M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Beam Therapeutics (BEAM) have?

Beam Therapeutics (BEAM) has a total debt of $162.06M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$68.14M.

Take Your Investments to a Whole New Level